Tolbutamide Hydroxylation by Hepatic Microsomes from Atlantic Salmon (Salmo Salar L.)

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2012 Feb 8

PMID 22311023

Authors

AnnaLotta Schiller Vestergren

Vladimir Zlabek

Jana Pickova

Galia Zamaratskaia

Affiliations

Soon will be listed here.

Abstract

Metabolic transformations of two substrates for human cytochrome P450 (CYP450) 2C9, tolbutamide and diclofenac, were investigated in hepatic microsomes from Atlantic salmon (Salmo salar L.). Tolbutamide hydroxylation followed Michaelis-Menten kinetics. Mean apparent Michaelis-Menten constant (K(m)) and maximum reaction velocity (V(max)) values for 4-hydroxytolbutamide (TBOH) formation were 0.09 ± 0.031 mM and 49.5 ± 6.03 pmol/min/mg, respectively. Addition of sulfaphenazole, an inhibitor for mammalian CYP2C9, in a range from 1 to 200 μM decreased formation of TBOH in a concentration-dependent manner, but not to 50%. Neither fluconazole, an inhibitor of human CYP2C9, nor ketoconazole, inhibitor of CYP1A and CYP3A in fish, affected TBOH formation. In contrast ellipticine, an inhibitor of CYP1A in fish inhibited TBOH formation with the IC(50) value of 12.1 μM. The rate of TBOH formation was competitively inhibited by 100 μM of sesamin in the incubations, but the degree of inhibition did not increase with increased sesamin concentration. Ethoxyresorufin hydroxylase (EROD) activity was inhibited by tolbutamide in a non-competitive manner (inhibition constant K(i) = 218 μM). Our data suggest that tolbutamide is metabolized by salmon microsomes with formation of TBOH. CYP1A might be involved in this reaction as suggested by decreased TBOH formation in the presence of ellipticine and decreased EROD activity in the presence of tolbutamide. Incubation of diclofenac with the microsomes yielded no metabolite formation, suggesting that salmon does not possess diclofenac-metabolizing activity.

References

Trattner S, Kamal-Eldin A, Brannas E, Moazzami A, Zlabek V, Larsson P . Sesamin supplementation increases white muscle docosahexaenoic acid (DHA) levels in rainbow trout (Oncorhynchus mykiss) fed high alpha-linolenic acid (ALA) containing vegetable oil: metabolic actions. Lipids. 2008; 43(11):989-97. DOI: 10.1007/s11745-008-3228-8. View

Burkina V, Zamaratskaia G, Randak T, Li Z, Fedorova G, Pickova J . Verapamil does not modify catalytic activity of CYP450 in rainbow trout after long-term exposure. Ecotoxicol Environ Saf. 2012; 79:148-152. DOI: 10.1016/j.ecoenv.2011.12.012. View

Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y . Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000; 28(4):475-81. View

Zamaratskaia G, Zlabek V . EROD and MROD as Markers of Cytochrome P450 1A Activities in Hepatic Microsomes from Entire and Castrated Male Pigs. Sensors (Basel). 2012; 9(3):2134-47. PMC: 3345832. DOI: 10.3390/s90302134. View

Zamaratskaia G, Zlabek V . Para-nitrophenol hydroxylation by fish liver microsomes: kinetics and effect of selective cytochrome P450 inhibitors. Fish Physiol Biochem. 2011; 37(4):969-76. DOI: 10.1007/s10695-011-9494-z. View

Kumar V, Rock D, Warren C, Tracy T, Wahlstrom J . Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos. 2006; 34(11):1903-8. PMC: 2377028. DOI: 10.1124/dmd.106.010249. View

WESTER M, Lasker J, Johnson E, Raucy J . CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000; 28(3):354-9. View

Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T . Metabolism of sesamin by cytochrome P450 in human liver microsomes. Drug Metab Dispos. 2010; 38(12):2117-23. DOI: 10.1124/dmd.110.035659. View

Bjornsson B, Stefansson S, McCormick S . Environmental endocrinology of salmon smoltification. Gen Comp Endocrinol. 2010; 170(2):290-8. DOI: 10.1016/j.ygcen.2010.07.003. View

10.

Bombardier E, Booth R, Green H, McKinley R . Metabolic adaptations of oxidative muscle during spawning migration in the Atlantic salmon Salmo salar L. Fish Physiol Biochem. 2009; 36(3):355-365. DOI: 10.1007/s10695-008-9300-8. View

11.

Rasmussen M, Ekstrand B, Zamaratskaia G . Comparison of cytochrome P450 concentrations and metabolic activities in porcine hepatic microsomes prepared with two different methods. Toxicol In Vitro. 2010; 25(1):343-6. DOI: 10.1016/j.tiv.2010.10.007. View

12.

Miners J, Smith K, Robson R, McManus M, Veronese M, Birkett D . Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol. 1988; 37(6):1137-44. DOI: 10.1016/0006-2952(88)90522-9. View

13.

Yasuda K, Ikushiro S, Kamakura M, Munetsuna E, Ohta M, Sakaki T . Sequential metabolism of sesamin by cytochrome P450 and UDP-glucuronosyltransferase in human liver. Drug Metab Dispos. 2011; 39(9):1538-45. DOI: 10.1124/dmd.111.039875. View

14.

Srivastava P, Yun C, Beaune P, Ged C, Guengerich F . Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol. 1991; 40(1):69-79. View

15.

Rettie A, Jones J . Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol. 2005; 45:477-94. DOI: 10.1146/annurev.pharmtox.45.120403.095821. View

16.

BELANGER P, St-Hilaire S . The characteristics of the microsomal hydroxylation of tolbutamide. Can J Physiol Pharmacol. 1991; 69(3):400-5. DOI: 10.1139/y91-061. View